Publications by authors named "Michael R Grever"

Claim this Profile
E
Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
Tamar Tadmor, Judit Demeter, Andrei Fagarasanu, Robert J Kreitman, Sameer A Parikh, Michael R Grever

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A Bhat, Mirela I Anghelina, Michael R Grever

EJHaem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Matthew R Avenarius, Ying Huang, Adam S Kittai, Seema A Bhat, Kerry A Rogers, Michael R Grever

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.
Kaitlin Annunzio, Michael Ozga, Ying Huang, Mirela Anghelina, Seema A Bhat, Michael R Grever

EJHaem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Pooja S Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J Pollauf, Amy Zheng, Michael R Grever

Leukemia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Pooja S Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J Pollauf, Amy Zheng, Michael R Grever

Leukemia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-inhibitor salvage therapy for hairy cell leukemia.
Michael R Grever

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
Adam S Kittai, Ying Huang, Kyle A Beckwith, Seema A Bhat, David A Bond, Michael R Grever

Am J Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M Stone, Alan Saven, Michael R Grever

Blood· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.
Jonathan M Hyak, Ying Huang, Kerry A Rogers, Seema A Bhat, Michael R Grever

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
Audrey M Sigmund, Ying Huang, Amy S Ruppert, Kami Maddocks, Kerry A Rogers, Michael R Grever

Leukemia· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Adam S Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V Abruzzo, Michael R Grever

Blood· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Nyla A Heerema, Natarajan Muthusamy, Qiuhong Zhao, Amy S Ruppert, Heather Breidenbach, Michael R Grever

Haematologica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Kerry A Rogers, Leslie A Andritsos, Lai Wei, Eric M McLaughlin, Amy S Ruppert, Michael R Grever

Blood· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
Xavier Troussard, Michael R Grever

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second cancer incidence in CLL patients receiving BTK inhibitors.
David A Bond, Ying Huang, James L Fisher, Amy S Ruppert, Dwight H Owen, Michael R Grever

Leukemia· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Caner Saygin, Karilyn Larkin, James S Blachly, Shelley Orwick, Apollinaire Ngankeu, Michael R Grever

Am J Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Robert Wesolowski, Daniel G Stover, Maryam B Lustberg, Abigail Shoben, Meng Zhao, Michael R Grever

Oncologist· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clara D. Bloomfield, M.D. (1942-2020): Legacy in Leukemia Research.
Michael R Grever

Oncologist· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogues.
Rebecca F Wang, Daniel Li, Gina J Kuehn, Leslie A Andritsos, Michael R Grever

J Am Acad Dermatol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutaneous adverse events associated with purine analogs in the treatment of hairy cell leukemia.
Rebecca F Wang, Gina J Kuehn, Leslie A Andritsos, Michael R Grever, Benjamin H Kaffenberger

Int J Dermatol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Jim H Hughes, Mitch A Phelps, Richard N Upton, Stephanie E Reuter, Yue Gao, Michael R Grever

Br J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib.
Daniel P Shenoi, Leslie A Andritsos, James S Blachly, Kerry A Rogers, Mollie E Moran, Michael R Grever

Blood Adv· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case 28-2018: A Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia.
Kerry A Rogers, James S Blachly, Michael R Grever

N Engl J Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Alice S Mims, Anjali Mishra, Shelley Orwick, James Blachly, Rebecca B Klisovic, Michael R Grever

Haematologica· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis